Study: Gammal 2023, Clinical Pharmacology and Therapeutics

Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype

Citation

Gammal RS, Pirmohamed M, Somogyi AA, Morris SA et al (2023). Clinical Pharmacology and Therapeutics. PubMed id 36049896.

Open on PubMed

Cards that cite this study (2)

Each card gives its own wording for who was tested, how and what was found.

  • G6PD deficiency: who carries it and what to avoid Tier B moderate

    B Medicines previously implicated as unsafe in G6PD deficiency (n=not stated in the abstract)

    Guideline based on a systematic review of gene-drug evidence and regulatory warnings.

    Medications are classed high, medium or low-to-no risk. High-risk drugs should be avoided, medium-risk drugs used with caution, and low-to-no-risk drugs given with standard precautions. The guideline replaces the earlier rasburicase guideline.

    As recorded in this card: Gammal RS, Pirmohamed M, Somogyi AA, Morris SA et al (2023), Clinical Pharmacology and Therapeutics, [consensus]

    Note: Abstract read; the drug table itself was not opened, so no drug is placed in a risk class on this card.

  • Haemoglobin and white cell ranges on your blood test Tier B moderate

    This card lists the study as a source. It records no separate finding for it. (), , [official]

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.